Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol

Pathology and Oncology Research

Volumn 18, Issue 1, 2012, Pages 43-48

  Váróczy, László ^a   Zilahi, Erika ^a   Gyetvai, Ágnes ^a   Kajtár, Béla ^b   Gergely, Lajos ^a   Sipka, Sándor ^a   Illés, Árpád ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Diffuse large B cell lymphoma; Fc gamma receptor IIIa polymorphism; Gene expression profile; Rituximab; Survival; Treatment response

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; FC RECEPTOR IIA; GENOMIC DNA; PREDNISOLONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; GERMINAL CENTER; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; PROGNOSIS; RECEPTORS, IGG; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 84855260118     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9414-7     Document Type: Article

References (21)

1. B Coiffier F Reyes Groupe d'Etude des Lymphomes de l'Adulte 2005 Best treatment of agressive non-Hodgkin's lymphoma: a French perspective Oncology (Williston Park) 19 7 15
2. N Nitsu 2010 Current treatment strategy of diffuse large B-cell lymphomas Int J Hematol 92 231 237 10.1007/s12185-010-0666-x
3. LH Sehn B Berry M Chhanabhai, et al. 2007 The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood 109 1857 1861 17105812 10.1182/blood-2006-08-038257 1:CAS:528:DC%2BD2sXjtFeqt7g%3D (Pubitemid 46348180)
4. IS Lossos D Morgensztern 2006 Prognostic biomarkers in diffuse large B-cell lymphoma J Clin Oncol 24 995 1007 16418498 10.1200/JCO.2005.02.4786 1:CAS:528:DC%2BD28Xitl2qtL4%3D (Pubitemid 46638855)
5. D Shan JA Ledbetter OW Press 1998 Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1644 1652 9473230 1:CAS:528:DyaK1cXht12gsbk%3D (Pubitemid 28110329)
6. N Villamor E Montserrat D Colomer 2003 Mechanism of action and resistance to monoclonal antibody therapy Sem Oncol 30 424 433 10.1016/S0093-7754(03) 00261-6 1:CAS:528:DC%2BD3sXntl2msbw%3D (Pubitemid 36999684)
7. HR Koene M Kleijer J Algra, et al. 1997 FcgRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell FcgRIIIa, idependently of the FcgRIIIa-48 L/R/H phenotype Blood 1997 1109 1114 (Pubitemid 27314146)
8. E Hatjiharissi X Lian DD Santos, et al. 2007 Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgRIIIa-158 V/V and V/F polymorphism Blood 110 2561 2564 17475906 10.1182/blood-2007-01-070656 1:CAS:528:DC%2BD2sXhtFCnsbjM (Pubitemid 47523179)
9. AA Alizadeh MB Eisen RE Davis, et al. 2000 Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503 511 10676951 10.1038/35000501 1:CAS:528:DC%2BD3cXht1Shtrg%3D (Pubitemid 30082188)
10. D Morgenszter MG Martin IS Lossos 2007 Gene expression profiling in diffuse large B-cell lymphoma Leuk Lymph 48 669 682 10.1080/10428190601186176 (Pubitemid 46605538)
11. CP Hans DD Weisenburger TC Greiner, et al. 2004 Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 275 282 14504078 10.1182/blood-2003-05-1545 1:CAS:528:DC%2BD2cXhsFGhsA%3D%3D (Pubitemid 38029949)
12. G Cartron H Watier J Golay, et al. 2004 From the bench to bedside: ways to improve rituximab efficacy Blood 104 2635 2642 15226177 10.1182/blood-2004- 03-1110 1:CAS:528:DC%2BD2cXpslKjs70%3D (Pubitemid 39434941)
13. G Cartron L Dacheux G Salles, et al. 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene Blood 99 754 758 11806974 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D (Pubitemid 34525533)
14. SP Treon M Hansen AR Branagan, et al. 2005 Polymorphisms in FcgRIIIa (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinaemia J Clin Oncol 23 474 481 15659493 10.1200/JCO.2005.06.059 1:CAS:528:DC%2BD2MXitVartro%3D (Pubitemid 46224224)
15. SS Farag IW Flinn R Modali, et al. 2004 Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukaemia Blood 103 1472 1474 14563637 10.1182/blood-2003-07-2548 1:CAS:528:DC%2BD2cXhsVSlurk%3D (Pubitemid 38168664)
16. E Carlotti GA Palumbo E Oldani, et al. 2007 Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab Hematologica 92 1127 1130 10.3324/haematol.11288 1:CAS:528:DC%2BD2sXhtFKrs77N (Pubitemid 350144222)
17. DW Kim HD Jung JG Kim, et al. 2006 FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma Blood 108 2720 2725 16609067 10.1182/blood-2006-01-009480 1:CAS:528:DC%2BD28XhtFWgtLzM
18. LD Sjö CB Poulsen M Hansen, et al. 2007 Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups Eur J Haematol 79 501 507 17986209 10.1111/j.1600-0609.2007.00976.x (Pubitemid 350126679)
19. H Nyman M Adde ML Karjalainen-Lindsberg, et al. 2007 Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood 109 4930 4935 17299093 10.1182/blood-2006-09-047068 1:CAS:528:DC%2BD2sXmt1Ogu7Y%3D (Pubitemid 46827791)
20. K Fu DD Weisenberger W Choi, et al. 2008 Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma J Clin Oncol 26 4587 4594 18662967 10.1200/JCO.2007.15.9277 1:CAS:528:DC%2BD1cXht1KqtLfI
21. N Mounier J Briere C Gisselbrecht, et al. 2003 Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 101 4279 4284 12576316 10.1182/blood-2002-11-3442 1:CAS:528:DC%2BD3sXktFKht7k%3D (Pubitemid 36857789)